Investors

Welcome to the investor relations section of the Polarean website

AIM Rule 26

The information disclosed in the investor relations section is to specifically ensure compliance with Rule 26 of the AIM rules (last updated on 4 April 2023).

In addition the investor relations section aims to deliver timely news and information updates to existing and potential investors.

Polarean Imaging Plc is a company incorporated and registered in England and Wales with registered number 10442853.

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space.  Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung function, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform, Polarean’s vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On December 23, 2022, the FDA granted approval for Polarean’s first drug device combination product, XENOVIEW^TM (xenon Xe 129 hyperpolarized). ¹²⁹Xe MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

The Board places great importance on the need for effective communication with investors and the media. To ensure that all existing and future stakeholders are able to track our progress and obtain updates as soon as available, we would encourage registration to our alert service.